Across the recent three months, 6 analysts have shared their insights on Absci (NASDAQ:ABSI), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ ...

Sean McClain, Founder and CEO, announced "Today marks a significant milestone for Absci. We have initiated our first-in-human clinical trial for ABS-101, officially making Absci a clinical stage ...

Absci Stock Performance ABSI opened at $2.88 on Monday. The firm has a market cap of $367.34 million, a P/E ratio of -3.10 and a beta of 2.19. Absci Co. has a 52-week low of $2.01 and a 52-week ...

Shares of Absci rose after it said the first human study of its inflammatory bowel disease treatment has started and that it expects to enter into additional partnerships--including one with a ...

Absci reported Q1 2025 revenue of $1.2M, with R&D expenses rising to $16.4M. Stock surged 8.1% in aftermarket trading to $3.20. Company transitioned to clinical-stage biotech, initiating first-in ...

Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ: TWST) a company enabling customers to succeed through its offering of ...